Waiv Raises $35M for AI Oncology Diagnostics

Waiv, formerly known as Owkin Dx, has successfully concluded a significant funding round, bringing its total capital raised to $35 million. This latest infusion of capital was spearheaded by CRB Digital Health III, the largest venture capital fund in Southern Europe focused exclusively on digital health, managed by CRB Health Tech. The investment underscores strong market confidence in Waiv's innovative approach to precision diagnostics in oncology.

The funding round saw participation from a robust syndicate of investors. Building upon the initial Series A investment led by OTB Ventures and Alpha Intelligence Capital in March 2026, this extension welcomed additional backing from Serena Data Ventures, Karista, and SistaFund. This broad investor base highlights the widespread recognition of Waiv's potential to transform cancer care through advanced AI.

Meriem Sefta, CEO and co-founder of Waiv, expressed enthusiasm for the additional capital, stating, "This investment additional is a clear signal of confidence in what we are building at Waiv." She further elaborated that the funds will accelerate the company's clinical deployment and commercial expansion. "With recent regulatory approvals and our platform already operational in clinical settings, this capital will enable us to move even faster, expanding our reach into more laboratories, reinforcing our commercial traction, and ultimately enhancing precision oncology care for more patients."

This financial milestone closely follows a critical regulatory achievement for Waiv. The company recently secured CE marking under the IVDR for two of its AI-powered precision tests: RlapsRisk® BC, designed for prognostic risk profiling in breast cancer, and MSIntuit® CRC, used for MSI screening in colorectal cancer. These approvals are pivotal, positioning Waiv to rapidly scale adoption among laboratories and healthcare providers across Europe and beyond. The precision diagnostics market, particularly in oncology, is experiencing substantial growth, driven by the increasing demand for personalized treatment strategies and advancements in AI and machine learning.

Ignasi Heras Vila, General Partner at CRB Health Tech, commented on the investment, noting, "Waiv is developing one of the most promising platforms at the intersection of artificial intelligence and precision oncology. Their ability to extract molecular-grade insights from routine pathology has the potential to redefine how diagnostic services are delivered at scale." He added that CRB's participation in this funding extension reflects a deep conviction in both the leadership team, including Meriem Sefta and Lionel Guillou, and the long-term impact of their technology.

The strategic deployment of these funds is expected to bolster Waiv's efforts in scaling its AI-driven diagnostic solutions. The company's technology aims to provide deeper insights from histopathology, enabling more accurate diagnoses and treatment decisions. As the healthcare industry increasingly embraces AI for diagnostic advancements, Waiv's progress signifies a notable development in the competitive healthtech sector, where early-stage funding rounds are crucial for navigating complex regulatory pathways and achieving market penetration.